Home /  About eNose


The current organization of The eNose Company was founded in 2013. We focus on disease screening using exhaled-breath analysis. For this purpose, a dedicated point-of-care electronic nose was developed (Aeonose). After finishing a number of pilot studies in oncology, infectious-, and neurological diseases, The eNose Company now focuses on colon cancer, lung cancer, tuberculosis, and fasting.

In 2014, the Aeonose received a CE-mark, and in 2015 the company was ISO 13485 certified.

Mission, Vision, & Values

The eNose Company has defined the following statements:

Mission Statement:

The eNose Company develops diagnostic tools for screening of diseases through exhaled breath in order to ease patients’ lives, provide physicians with additional diagnostic tools, and lower the burden of the healthcare community.

Company Vision:

We aim at becoming the golden standard for disease screening, in particular population screening, using exhaled-breath analysis with our eNose technology. Examples include colon cancer, lung cancer, and tuberculosis.

This could be accomplished by applying advanced machine learning tools at large numbers of breath profiles.

Company Values:

Integrity, Teamwork, Committed to success.